Role of estrogen in postmenopausal depression

Neurology

Volumn 48, Issue 5 SUPPL. 7, 1997, Pages

  Halbreich, Uriel ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ANTIDEPRESSANT AGENT; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; IMIDAZOLINE RECEPTOR; IMIPRAMINE; MEDROXYPROGESTERONE ACETATE; MONOAMINE; NORADRENALIN; PROGESTERONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; COGNITION; DEPRESSION; ESTROGEN THERAPY; FEMALE; HUMAN; MOOD; POSTMENOPAUSE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RECEPTOR BINDING; SEROTONINERGIC SYSTEM; TRANSDERMAL DRUG ADMINISTRATION; WELLBEING;

EID: 0030918340     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.5_suppl_7.16s     Document Type: Article

References (58)

1. Belchetz P. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-1071.
2. Lindsay R. Why do oestrogens prevent bone loss? Baillieres Clin Obstet Gynaecol 1991;5:837-852.
3. Stampfer M, Colditz G, Willet W, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
4. American College of Obstetricians and Gynecologists. Hormonal replacement therapy. Technical bulletin #166. Washington: American College of Obstetricians and Gynecologists, 1992.
5. Sevringhaus EL. Use of folliculin in involutional states. Am J Obstet Gynecol 1933;25:361-368.
6. Wiesbader H, Kurzrok R. Menopause: consideration of symptoms, etiology, and treatment by means of estrogens. Endocrinology 1938;23:32-38.
7. McEwen BS. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991;12:141-147.
8. Luine VN, Khylchevskaya R, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res 1975;86:293-306.
9. Halbreich U, Bakhai Y, Bacon KB, Goldstein S, Endicott J, Lesser J. Screening and selection process for studies of menstrually-related changes. J Psychiatr Res 1989;23:65-72.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed revised. Washington: American Psychiatric Association Press, 1987.
11. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. Estrogen augments serotonergic activity in post menopausal women. Biol Psychiatry 1995;37:434-441.
12. Mueller EA, Murphy DL, Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab 1985;61:1179-1174.
13. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity, and recurrence. J Affect Disord 1993;29:85-96.
14. Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. Arch Gen Psychiatry 1977;34:98-111.
15. Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU. Sex differences in rates of depression: cross-national perspectives. J Affect Disord 1993;29:77-84.
16. Weissman MM. Epidemiology of major depression in women. Presented at the American Psychiatric Association Annual Meeting, May 4, 1996, New York, NY.
17. Oppenheim G. Estrogen in the treatment of depression: neuropharmacological mechanisms. Arch Gen Psychiatry 1986;43: 569-573.
18. Schneider MA, Brotherton PL, Hailes J. The effect of exogenous oestrogens on depression in menopausal women. Med J Aust 1977;2:162-163.
19. Shapira B, Oppenheim G, Zohar J, et al. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry 1985;20:576-579.
20. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract 1981:31:134-140.
21. Coope J, Thomson J, Poller L. Effects of "natural estrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975:4:139-143.
22. Prange AJ. Estrogen may well affect response to antidepressant. JAMA 1972;219:143-144.
23. Stahl S. Role of hormone therapies for refractory depression. Presented at the American Psychiatric Association Annual Meeting, May 4, 1996, New York, NY.
24. Michael C, Kantor H, Shore H. Further psychometric evaluation of older women - the effect of estrogen administration. J Gerontol 1970;25:337-341.
25. Aylward M. Estrogens and plasma tryptophan levels in perimenopausal patients. In: Campbell S, ed. The management of the menopause and post-menopausal years. Baltimore: University Park Press, 1976:135-147.
26. Furuhjelm M, Carlstrom K. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate. Acta Obstet Gynecol Scand 1977;56:351-361.
27. Furuhjelm M, Fedor-Freybergh P. The influence of estrogens on the psyche in climacteric and post-menopausal women. In: van Keep PA, Albeuax M, Greenblatt R, eds. Consensus on menopause research. Baltimore: University Press, 1976:84-93.
28. Ditkoff EC, Crary WG, Cristo M, Lobo R. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-995.
29. Best NR, Rees MP, Barlow DH, Cowen PJ. Effect of estradiol implant on noradrenergic function and mood in menopausal subjects. Psychoneuroendocrinology 1992;17:87-93.
30. Palinkas LA, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol 1992; 80:30-36.
31. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. Br Med J 1993;307:836-40.
32. Limouzin-Lamothe M, Mairon N, Joyce CR, LeGal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618-624.
33. Hackman B, Galbraith D. Replacement therapy with piperazine oestrone sulfate ('Harmogen') and its effect on memory. Curr Med Res Opin 1976;4:303-306.
34. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977;4:31-47.
35. Fedor-Freybergh P. The influence of oestrogens on the well-being and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand 1977;64:3-69.
36. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
37. Caldwell BM, Watson RI. Evaluation of psychologic effects of sex hormone administration in aged women: results of therapy after 6 months. J Gerontol 1952;7:228-244.
38. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993; 269:2637-2641.
39. Kampen D, Sherwin B. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83: 979-983.
40. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system - senile dementia (Alzheimer's type). J Steroid Biochem 1989;34:521-525.
41. Mortel K, Meyer J. Estrogen replacement therapy and risk of dementia [abstract]. Neurology 1994;44(suppl #2):A208.
42. Ohkura T, Isse K, Akazawa K, et al. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1994;1:125-130.
43. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995;6:99-107.
44. Halbreich U, Lumley LA, Palter S, Manning C, Gengo F, Joe SH. Possible acceleration of age effects on cognition following menopause. J Psychiatr Res 1995;29:153-163.
45. Halbreich U, Bernardis B, Vedella J, Manning C, Gengo F. Effect of an estrogen antagonist and estrogen on mood and cognition. Presented at the Annual Meeting of the Society of Biological Psychiatry, May, 1993, San Francisco, CA.
46. Halbreich U. Estrogen as a potential psychotropic medication. Presented at the 26th Congress of the International Society of Psychoneuroendocrinology, September, 1995, Munich, Germany.
47. Gengo F, Manning C. A review of the effects of antihistamines on mental processes related to automobile driving. J Allergy Clin Immunol 1990;86:1034-1039.
48. Reitan RM, Wolfsen D. The Halstead-Reitan neuropsychology test battery: theory and clinical interpretation. Tucson, AZ: Neuropsychology Press, 1985.
49. Wechsler D. Manual for the Wechsler adult intelligence scale - revised. New York: Psychological Corporation, 1981.
50. DeFilippis NA, McCampbell E. Manual for the booklet category test: research and clinical form. Odessa, FL: Psychological Assessment Resources, 1987.
51. Ekstrom RB, French JW, Harman HH, Dermen D. Manual for kit of factor-referenced cognitive tests. Princeton, NJ: Educational Testing Services, 1976.
52. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980;10:189-209.
53. Williams D, Moley K. Progestin replacement in the menopause: effects on the endometrium and serum lipids. Curr Opin Obstet Gynecol 1994;6:284-292.
54. Hammerback S, Backstrom T, Holst J, et al. Cyclical changes produced by sequential estrogengastagen therapy. J Psychosom Obstet Gynaecol 1983;23:201-208.
55. Magos AL, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986;93:1290-1296.
56. Magos AL, Colins WP, Studd JW. Management of the premenstrual syndrome by subcutaneous implants of oestradiol. J Psychosom Obstet Gynaecol 1984;3:93-99.
57. Halbreich U. Premenstrual syndromes. In: Halbreich U, ed. Psychiatric issues in women. London: Baillaire-Tyndall, 1996: 667-686.
58. Lobo R, McCormick W, Singer F, Roy S. Depo-medroxy-progesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1-5.